Axogen, Inc. (AXGN) stock
- 1earnings: AXGN Q2 2026 earnings scheduled (scheduled 2026-07-29)
- 2No macro events in the recency window.
- 3Revenue growth 22.4% YoY, net margin -13.2%.
Factor grades
As of 2026-07-28Percentile grades within the stock’s sector, computed nightly from SEC filings. Statistical ranking, not investment advice.
- No macro events in the recency window.
- earnings: AXGN Q2 2026 earnings scheduled (scheduled 2026-07-29)
- earningsScheduled 2026-07-29AXGN Q2 2026 earnings scheduledReported EPS 0.12 vs. estimate 0.13.BEARISH
- Revenue growth 22.4% YoY, net margin -13.2%.
- Forward P/E —, FCF $0.0B.
- Earnings beat 50% of trailing 4 quarters.
- First Light Asset Management, LLC4.0M sh · -23.51% QoQ
- Blackrock Inc.3.9M sh · +4.07% QoQ
- Morgan Stanley3.1M sh · +20.72% QoQ
- Vanguard Capital Management LLC2.3M sh · +100.00% QoQ
- ArrowMark Colorado Holdings LLC1.9M sh · +29.92% QoQ
- No news in the recency window.
- Signal shifted from neutral since the last brief.
Key fundamentals
Trailing-twelve-month figures computed by Meaterm from SEC filings, refreshed nightly.
Related Electromedical & Electrotherapeutic Apparatus stocks
Frequently asked questions
What are the AXGN factor grades?
Meaterm scores Axogen, Inc. (AXGN) on four factors — valuation, growth, profitability and momentum — plus a composite. Each grade is a percentile ranking against the stock's sector, computed nightly from SEC-filed financial data. Grades are statistical rankings, not investment advice or a recommendation to trade.
How is the fair value estimate for AXGN calculated?
The estimate is the median of several peer-multiple implied values — peer P/E, EV/EBITDA, P/S and P/B applied to the company's own fundamentals — plus a sell-side consensus target when one is available. Peers come from the same industry, matched by size. It is a statistical reference point, not a price target and not investment advice.
Where does the data on this page come from?
Fundamentals and factor grades are computed by Meaterm from SEC filings and refreshed nightly. Positioning context comes from public CFTC and FINRA releases, and macro series from FRED. Every signal, grade and estimate shown is Meaterm’s own computation.
Is AXGN a good stock to invest in?
Meaterm does not answer that question. This page shows how Axogen, Inc. (AXGN) ranks statistically against sector peers on valuation, growth, profitability and momentum, and where its price sits relative to a peer-multiple estimate. Use it as research context alongside your own analysis — nothing on this page is investment advice.
How often is this page updated?
Factor grades, fundamentals and the company profile refresh nightly after each trading day. The brief layers — macro, catalysts, positioning and news — are composed when the page loads, and the fair value estimate is recomputed with recent quotes during the day.